Generic Elocon Availability

Elocon is a brand name of mometasone topical, approved by the FDA in the following formulation(s):

ELOCON (mometasone furoate - cream; topical)

ELOCON (mometasone furoate - lotion; topical)

ELOCON (mometasone furoate - ointment; topical)

Has a generic version of Elocon been approved?

A generic version of Elocon has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Elocon and have been approved by the FDA:

mometasone furoate cream; topical

  • Manufacturer: FOUGERA PHARMS
    Approval date: April 8, 2005
    Strength(s): 0.1% [AB]
  • Manufacturer: G AND W LABS
    Approval date: May 22, 2006
    Strength(s): 0.1% [AB]
  • Manufacturer: GLENMARK GENERICS
    Approval date: May 28, 2008
    Strength(s): 0.1% [AB]
  • Manufacturer: TARO
    Approval date: December 21, 2004
    Strength(s): 0.1% [AB]
  • Manufacturer: TOLMAR
    Approval date: April 18, 2007
    Strength(s): 0.1% [AB]

mometasone furoate lotion; topical

  • Manufacturer: FOUGERA PHARMS
    Approval date: November 29, 2007
    Strength(s): 0.1% [AB]
  • Manufacturer: G AND W LABS
    Approval date: November 21, 2007
    Strength(s): 0.1% [AB]
  • Manufacturer: GLENMARK GENERICS
    Approval date: August 9, 2010
    Strength(s): 0.1% [AB]
  • Manufacturer: PERRIGO
    Approval date: April 6, 2005
    Strength(s): 0.1% [AB]
  • Manufacturer: TARO
    Approval date: March 15, 2006
    Strength(s): 0.1% [AB]
  • Manufacturer: TOLMAR
    Approval date: November 21, 2007
    Strength(s): 0.1% [AB]

mometasone furoate ointment; topical

  • Manufacturer: FOUGERA PHARMS
    Approval date: March 28, 2005
    Strength(s): 0.1% [AB]
  • Manufacturer: G AND W LABS
    Approval date: June 20, 2006
    Strength(s): 0.1% [AB]
  • Manufacturer: GLENMARK GENERICS
    Approval date: May 28, 2008
    Strength(s): 0.1% [AB]
  • Manufacturer: PERRIGO NEW YORK
    Approval date: March 18, 2002
    Strength(s): 0.1% [AB]
  • Manufacturer: TARO
    Approval date: December 3, 2004
    Strength(s): 0.1% [AB]
  • Manufacturer: TOLMAR
    Approval date: November 14, 2003
    Strength(s): 0.1% [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Elocon. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Elocon.

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • April 19, 2016 - NEW PRODUCT

See also...

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
ABProducts meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (i.e., AB1, AB2, AB3, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.
Advertisement
Close

Recommended

(web1)